Intracellular claudin-1 at the invasive front of tongue squamous cell carcinoma is associated with lymph node metastasis

Daisuke Yamamoto1 | Kou Kayamori2 | Kei Sakamoto2 | Maiko Tsuchiya2 | Tohru Ikeda2 | Hiroyuki Harada3 | Tetsuya Yoda1 | Tetsuro Watabe4 | Miki Hara-Yokoyama4

1Department of Maxillofacial Surgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan
2Department of Oral Pathology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan
3Department of Oral and Maxillofacial Surgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan
4Department of Biochemistry, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan

Correspondence
Miki Hara-Yokoyama, Department of Biochemistry, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan. Email: m.yokoyama.bch@tmd.ac.jp

Funding information
Tokyo Medical and Dental University, Grant/Award Number: 17K12005

Abstract
Claudins are the major component of tight junctions, which form a primary barrier to paracellular diffusion and maintain cell polarity in normal epithelia and endothelia. In cancer cells, claudins play additional roles besides serving as components of the tight junctions, and participate in anoikis or invasion. Among the claudin family proteins, claudin-1 has the most promising potential, both diagnostically and prognostically, in many types of cancers, including oral, gastric, liver, and colon cancers. However, conflicting results have been reported in relation to the degree of claudin-1 expression and the prognosis, suggesting that the expression level of claudin-1 alone is not sufficient to analyze the relationship between claudin-1 and cancer progression. As endocytic trafficking of claudin-1 has been reported in several epithelial cell types in vitro, we aimed to determine whether intracellular localization of claudin-1 is the missing aspect between claudin-1 and cancer. We investigated the expression of claudin-1 in 83 tongue squamous cell carcinoma (TSCC) pathological specimens. Although the expression level of claudin-1 based on immunohistochemistry was not associated with TSCC progression, within the high claudin-1 expression group, the incidence of intracellular localization of claudin-1 was correlated with cervical lymph node metastasis. In an in vitro experiment, claudin-1 was constitutively internalized in TSCC-derived cells. Motility of TSCC-derived cells was increased by deficiency of claudin-1, suggesting that the decrease in cell-surface claudin-1 promoted the cell migration. Therefore, intracellular localization of claudin-1 at the invasion front may represent a promising diagnostic marker of TSCC.

KEYWORDS
claudin-1, endocytosis, invasion front, metastasis, tongue squamous cell carcinoma

Abbreviations: CPZ, chlorpromazine; IMP, imipramine; OSCC, oral squamous cell carcinomas; TSCC, tongue squamous cell carcinoma.
INTRODUCTION

The oral cavity is the major site of head and neck cancer, with approximately 300,000 cases and 145,000 deaths reported annually worldwide. The primary sites of cancer within the oral cavity are the tongue and the floor of the mouth, or the buccal mucosa. Surgical removal is followed by postoperative declines in speech and feeding, causing a serious decline in quality of life (QOL). Histologically, most oral cancers are squamous cell carcinomas that infiltrate into mesenchymal tissues. The important factor affecting the survival prognosis is metastasis.

Claudin-1 belongs to the claudin superfamily of proteins, which are structural and functional components of tight junctions. Claudin-1 is classified as a paracellular barrier-forming claudin. Mice deficient in claudin-1 die of dehydration within a day of birth, indicating that claudin-1 in skin epidermal sheets is crucial for organizing the water barrier on the entire surface of the body. Recent studies have suggested that claudin-1 also plays a role unrelated to tight junctions in cancer, such as the activation of tumor necrosis factor (TNF)-α or c-Abl-ERK signaling. The resistance to anoikis in a Src-dependent method and the enhancement of invasive activity through the activation of matrix metalloproteinases.

Low claudin-1 expression is associated with shorter overall survival and higher tumor grades in lung adenocarcinoma, prostatic adenocarcinoma, rectal cancer, and breast cancer. In these cancers, claudin-1 is a metastasis suppressor. In contrast, in colon cancer, some studies have shown that claudin-1 overexpression has a good prognostic value (fewer metastases and less aggressive), whereas other studies have shown that claudin-1 overexpression is linked with increased invasion. Accordingly, although claudin-1 has the potential to be a biomarker with diagnostic and prognostic values in oral, gastric, liver, and colon cancers, the seemingly contradictory results imply that the expression level of claudin-1 alone is not sufficient to analyze the relationship between claudin-1 and cancer metastasis.

The tight junction protein complex reportedly has a dynamic structure, undergoing rapid and continuous molecular remodeling in the steady state in MDCK cells. A functional endosomal sorting complex required for transport (ESCRT) is involved in the constitutive recycling of claudin-1 between the plasma membrane and intracellular vesicles in MDCK cells. Furthermore, there is growing evidence linking endocytosis and the regulation of cell migration. Thus, we hypothesized that a factor related to the membrane dynamics of claudin-1 would be equivalent to the missing link between claudin-1 and cancer metastasis.

Cancer cell morphology at the invasion front has recently attracted attention as a prognostic factor. For example, in colon cancer, the correlation between tumor budding at the invasion front of the lesion and regional lymph node metastasis has been reported. In oral cancer, the YK classification based on the infiltration mode has been used as one of the diagnostic criteria.

Overexpression of the claudin-1 (CLDN1) gene is significantly correlated with advanced disease stage in OSCC based on molecular classifications of oral cancer by cDNA microarrays.
data. Percentages of claudin-1-positive neoplastic cells were semiquantitatively assessed, and proportion scores of 1, 2, 3, and 4 were given when the percentages of positive cells were 25% or less, 26%-50%, 51%-75%, and 76%-100%, respectively. Intensities of immunoreactivity were categorized into negative (score 0), low (score 1), moderate (score 2), and high (score 3) as shown in Figure 1. The final score of claudin-1 immunoreactivity levels was obtained by multiplying the proportion score by the intensity score. Cases were classified into high if the scores were 4 or higher and into low if the scores were 3 or less.

For assessment of the localization of claudin-1, five square regions were selected from the claudin-1-positive invasion front for each case. Cases were classified as "intracellular" when the exclusive membrane localization of claudin-1 was not observed in three or more regions. Otherwise, they were classified as "membrane".

2.4 | Confocal laser scanning microscopy

For immunofluorescence staining, a mouse monoclonal anti-claudin-1 antibody (1C5-D9) (H00009076-M01; Novus Biologicals) and an Alexa Fluor 488-conjugated anti-mouse antibody were used. Immunofluorescent images were captured and analyzed with a Leica TCS SP8 confocal microscope (Leica).
2.5 | Cell culture and reagents

Human tongue squamous cell carcinoma cell line (SAS) was obtained from Japanese Collection of Research Bioresources. SAS cells were maintained in DMEM: high glucose (08458; Nacalai Tesque), supplemented with 10% FBS (Sigma-Aldrich), l-penicillin (50 U/mL), and streptomycin (50 μg/mL), at 37°C in a 5% CO₂ atmosphere. Chlorpromazine hydrochloride (C8138) was obtained from Sigma-Aldrich and imipramine hydrochloride (I0971) was from Tokyo Chemical Industry.

### TABLE 1 | Clinicopathological features of 83 tongue squamous cell carcinoma patients

| Feature                        | No. of patients (%) |
|--------------------------------|---------------------|
| **Gender**                     |                     |
| Male                           | 50                  |
| Female                         | 33                  |
| **Age (y)**                    |                     |
| Median                         | 65.36               |
| SD                             | 15.41               |
| **T stage**                    |                     |
| Carcinoma in situ (cis)        | 5 (6.0)             |
| T1                             | 43 (51.8)           |
| T2                             | 25 (30.1)           |
| T3                             | 9 (10.8)            |
| T4a                            | 1 (1.2)             |
| T4b                            | 0 (0.0)             |
| **TNM stage**                  |                     |
| I                              | 43 (51.8)           |
| II                             | 18 (21.7)           |
| III                            | 5 (6.0)             |
| IVa                            | 3 (3.6)             |
| IVb                            | 9 (10.8)            |
| IVc                            | 0 (0.0)             |
| **YK classification**          |                     |
| YK -1                          | 2 (2.4)             |
| YK-2                           | 10 (12.0)           |
| YK-3                           | 35 (42.2)           |
| YK-4c                          | 25 (30.1)           |
| YK-4d                          | 6 (7.2)             |
| **Differentiation**            |                     |
| Well                           | 42 (50.6)           |
| Moderate                       | 29 (34.9)           |
| Poor                           | 7 (8.4)             |
| **Local recurrence**           |                     |
| Positive                       | 5 (2)               |
| Negative                       | 38 (38)             |
| **Cervical lymph node metastasis** |                |
| Positive                       | 17 (10)             |
| Negative                       | 26 (30)             |
| **Distant organ metastasis**   |                     |
| Positive                       | 2 (1)               |
| Negative                       | 41 (39)             |

### TABLE 2 | Relationship between claudin-1 expression and clinicopathological features of 83 tongue squamous cell carcinoma patients

| Feature                        | No. of patients |
|--------------------------------|-----------------|
| **Claudin-1 expression**       |                 |
| **Gender**                     |                 |
| Male                           | 24 (26)         |
| Female                         | 19 (14)         |
| **Age (y)**                    |                 |
| ≤69                           | 20 (15)         |
| >69                           | 23 (25)         |
| **T stage**                    |                 |
| T1                            | 24 (19)         |
| T2-4                          | 18 (17)         |
| **TNM stage**                  |                 |
| I                             | 24 (19)         |
| I-IV                          | 18 (17)         |
| **Differentiation**            |                 |
| Well                           | 24 (18)         |
| Moderate                       | 14 (15)         |
| Poor                           | 4 (3)           |
| **YK classification**          |                 |
| YK -1                          | 0 (2)           |
| YK-2                           | 3 (7)           |
| YK-3                           | 26 (9)          |
| YK-4c                          | 10 (15)         |
| YK-4d                          | 3 (3)           |
| **Local recurrence**           |                 |
| Positive                       | 5 (2)           |
| Negative                       | 38 (38)         |
| **Cervical lymph node metastasis** |             |
| Positive                       | 17 (10)         |
| Negative                       | 26 (30)         |
| **Distant organ metastasis**   |                 |
| Positive                       | 2 (1)           |
| Negative                       | 41 (39)         |

2.6 | Endocytosis of claudin-1

Claudin-1 endocytosis was evaluated based on the modified cell-surface assay using EZ-link sulfo-NHS-biotin (21 331; Pierce), as described previously. Materials recovered by Neutravidin beads (29 200; Pierce) were subjected to 12% SDS-PAGE under reducing conditions, and then transferred to a PVDF membrane. The membrane was incubated with 4% Block Ace (Yukijirushi) for 1 hour and then incubated with an anti-claudin-1, rabbit polyclonal
antibody (ab15098; Abcam). An HRP-conjugated anti-rabbit antibody (#7074; Cell Signaling Technology) was used as the secondary antibody. Immunoblot signals of claudin-1 were detected using the ECL Western Blotting Detection Reagent (RPN2109; GE Healthcare) and quantified by the FUSION chemiluminescence imaging system (VILBER).

### 2.7 Cell motility assay

SAS cells were seeded at a density of $2 \times 10^4$/well into 6-well plates, 48 hours before the experiment. Cell motility was monitored with a BZ-X800 time-lapse imaging system (KEYENCE). Images were analyzed using ImageJ software (National Institutes of Health), and cell

---

**FIGURE 2** Typical cases of tongue squamous cell carcinoma (TSCC) showing either intracellular (A-E) or membrane-confined localization (F-H) of claudin-1 at the invasion front. Immunohistochemical (A, F) and immunofluorescence (B-E, G, H) staining of claudin-1 in two cases of TSCC. Upper and lower boxed areas in (A) show the center and the invasion front of the lesion, which are magnified in (B) and (D), respectively. The boxed area in (F) shows the invasion front of the lesion in another TSCC, which is magnified in (G). The boxed areas in (B, D, G) are further magnified in (C, E, H), respectively. See also Videos S1-S3, which correspond to (C, E, H), respectively. Scale bars: 300 μm (A, F), 25 μm (B, D, G), and 5 μm (C, E, H)
tracking was done using the Manual Tracking plugin. Total distance traveled was determined by tracking the movement of the cell gravity center, and its coordinates were used to calculate the distances.

2.8 | Establishment of SAS cells deficient for the claudin-1 gene

Claudin-1-knockout SAS cells were established using the clustered regularly interspaced short palindromic repeats/CRISPR associated protein 9 (CRISPR/CAS9)-mediated genome editing system. Guide RNA (gRNA) target sequences for claudin-1: 5′-CCTATGCCGGCGACACACATCGTG-3′ (gRNA #1) and 5′-CCTGCGTGTCGCAGAGCACCGGG-3′ (gRNA #2) (PAM sequence underlined) were designed with CRISPRdirect (https://crispr.dbcls.jp). Expression cassette of each gRNA was incorporated into the pX330 plasmid, carrying the human Cas9 expression cassette. Efficiency of both gRNAs to induce double strand breaks was validated by reconstituted EGFP fluorescence, as described previously. After transfection of SAS cells with the pX330 plasmid, knockout clones were isolated by carrying out limiting dilution. Effective knockout of claudin-1 was confirmed at the protein

![Figure 3: Assessment of tongue squamous cell carcinoma according to membrane localization of claudin-1 at the invasion front.](image-url)
level by immunoblotting with an anti-human claudin-1 antibody (ab15098).

2.9 | Statistical analysis

In clinical specimens, Fisher’s exact test or Pearson’s chi-squared test were carried out with the statistical software ‘EZR’ (Easy R). For the in vitro experiments, significant differences between means were determined using Student’s t test. P <.05 was considered statistically significant.

3 | RESULTS

3.1 | Claudin-1 expression level is not associated with TSCC progression

Paraffin-embedded sections of TSCC specimens from 83 individual patients were examined for claudin-1 immunoreactivity. Patient details are provided in Table 1. Various degrees of claudin-1 immunoreactivities were observed within the basal layers of the epithelium and metastatic lesions as shown in Figure 1. Claudin-1 expression was not observed in the surrounding mesenchymal...
YAMAMOTO et al

TABLE 3 Relationship between localization of claudin-1 expression and clinicopathological features of claudin-1-high patients

|                | Intracellular | Membrane |
|----------------|---------------|----------|
| No. of patients|               |          |
| Differentiation|               |          |
| Well           | 9             | 15       |
| Moderate       | 8             | 6        |
| Poor           | 4             | 0        | P = .06 |
| YK classification|         |          |
| YK-1           | 0             | 0        |
| YK-2           | 0             | 3        |
| YK-3           | 12            | 14       |
| YK-4c          | 6             | 4        |
| YK-4d          | 3             | 0        | P = .10 |
| Local recurrence|             |          |
| Positive       | 4             | 1        |
| Negative       | 17            | 20       | P = .34 |
| Cervical lymph node metastasis|     |          |
| Positive       | 15            | 2        |
| Negative       | 6             | 19       | P = .000929 |
| Distant organ metastasis|     |          |
| Positive       | 2             | 0        |
| Negative       | 19            | 21       | P = .48 |

tissue. All of the cases were classified into either the high or low expression group, based on both the intensity and proportion scores. Results are shown in Table 2. There were no significant differences in any of the evaluation items between the two groups.

3.2 | Intracellular localization of claudin-1 at the invasion front is associated with cervical lymph node metastasis

In some specimens, we noticed a difference in claudin-1 immunostaining between the center and the invasion front of the lesion, which may be due to an altered localization of claudin-1 (Figure 2A).

Therefore, claudin-1 immunoreactivity was observed by immunofluorescence using confocal microscopy. Claudin-1 was predominantly localized at the membrane in the center of the lesion (Figure 2B,C), but intracellular claudin-1 localization was also observed at the invasion front (Figure 2D,E), as detected by 3-D images (Videos S1 and S2, respectively). Claudin-1 is likely localized to intracellular vesicles. Although nuclear localization of claudin-1 was reported in the case of colon cancer, the nucleus was not the main site of localization in the present study. Although intracellular localization of claudin-1 was observed in some specimens, exclusive membrane localization was maintained at the invasion front in other specimens (Figure 2F-H and Video S3).

Thus, we developed a scoring system by which the localization of claudin-1 at the invasion front was evaluated as either “membrane” (Figure 3) or “intracellular” (Figure 4). Among the cases categorized as having high claudin-1 expression, the frequency of cervical lymph node metastasis was significantly higher in the “intracellular claudin-1” group than in the “membrane claudin-1” group, as shown in Table 3.

3.3 | Claudin-1 is constitutively endocytosed in TSCC-derived cells

SAS cells are derived from TSCC. Using these cells, we investigated the ability of claudin-1 to be endocytosed. For this purpose, cell-surface claudin-1 was biotinylated by a cleavable, cell-impermeable crosslinker (Figure 5A). After incubation, biotinylated residues remaining on the cell surface were either left or stripped off. The biotinylated claudin-1 was then recovered with Neutravidin beads and evaluated by immunoblotting. The biotinylated claudin-1 that remained after stripping was considered to be endocytosed from the cell surface. As shown in Figure 5A,B, a substantial part of the biotinylated claudin-1 was resistant to stripping, which is a biochemical demonstration of the endocytosis of claudin-1 in SAS cells. In addition, endocytosis of claudin-1 in SAS cells was investigated in the presence of an inhibitor of clathrin-dependent endocytosis, CPZ, and an inhibitor of macropinocytosis, IMP. Addition of IMP decreased the extent of stripping-resistant claudin-1, suggesting that IMP inhibited claudin-1 endocytosis. Although the addition of CPZ was also found to decrease the extent of stripping-resistant claudin-1, the effect was not statistically significant. However, immunofluorescence staining of claudin-1 in SAS cells
revealed that the abundant intracellular staining of claudin-1 was suppressed in the presence of CPZ or IMP (Figure 5C). These results suggested that claudin-1 is constitutively endocytosed in TSCC cells. We considered that the loss of membrane location of claudin-1 is mainly caused by macropinocytosis with some contribution of clathrin-dependent endocytosis.
Inhibition of endocytosis suppresses the motility of SAS cells

The molecular machineries required for clathrin-dependent endocytosis are reportedly involved in the regulation of migration. As constitutive endocytosis of claudin-1 was shown in SAS cells (Figure 5), we examined the effects of endocytosis inhibitors (CPZ and IMP) on the migration of SAS cells. For this purpose, we used the cell tracking method of recent studies. As shown in Figure 6 (Figures S4-S6), total migrated distance was decreased by the addition of CPZ and IMP, suggesting that inhibition of endocytosis suppresses cell migration.

CRISPR/CAS9-mediated knockout of claudin-1 in SAS cells accelerates cell motility

Finally, we investigated whether claudin-1 is involved in cell motility in SAS cells. For this purpose, claudin-1-knockout SAS cells were established by CRISPR/CAS9-mediated genome editing (Figure 7A). As shown in Figure 7B-E (Figures S7-S9, respectively), total migrated distance was increased in two independent clones of claudin-1-knockout SAS cells. These results suggested that claudin-1 has a great impact on the migration of SAS cells.

Both clathrin-dependent endocytosis and micropinocytosis are involved in the regulation of cell migration. Thus, the possibility remained that the effects of CPZ and IMP (Figure 6) are independent of their actions on the endocytosis of claudin-1. However, considering that deficiency of claudin-1 promoted cell motility (Figure 7), it can be speculated that the disappearance of claudin-1 from the membrane by endocytosis promotes cell migration.

DISCUSSION

Numerous epithelial-derived cancers show altered expression patterns of claudins. In the present study, the expression level of claudin-1, as assessed by immunohistochemistry, was not associated with disease progression in 83 TSCC. However, within the high claudin-1 expression group, the loss of the exclusive membrane localization of claudin-1 (intracellular localization of claudin-1) at the invasion front was associated with cervical lymph node metastasis. This result suggested that the intracellular localization of claudin-1 at the invasion front could be a potential marker of metastasis in TSCC.

Previously, claudin-1 overexpression was reported to be associated with invasive pathological characteristics in OSCC in two independent studies which analyzed various regions in the oral cavity. The areas in one study (total 99 patients) included the tongue (44%), floor of mouth (24%), floor of mouth and tongue (13%), alveoli (13%), buccal mucosa (5%), and retromolar trigone (1%). Those of the other study (total 45 patients) included the gingiva (38%), tongue (16%), floor of mouth (18%), buccal mucosa (13%), hard palate (7%), and alveolar mucosa (9%). In the
In the present study, we focused on TSCC, which may explain the different conclusions obtained between the previous and present studies. As for our study, considering that the opposite conclusions of poor\textsuperscript{18,19} and good\textsuperscript{11,16,17} prognoses have been reported for high expression of claudin-1 in colon cancer,\textsuperscript{15} it is possible that opposite types of TSCC coexist.

As the immunoreactivity of claudin-1 was restricted to the lesion in TSCC, claudin-1 in the cancer lesion may have a direct effect on invasion, rather than on the surrounding mesenchymal tissue. Expression of claudin-1 in cancer is regulated in various ways: claudin-1 is upregulated by β-catenin/Tcf signaling in human colorectal cancers,\textsuperscript{19} and epigenetically silenced in estrogen receptor-positive breast cancer.\textsuperscript{41} Thus, the expression level of claudin-1 in cancer cells could be context-dependent. During epithelial-mesenchymal transition (EMT), transcription factors Slug and Snail act as repressors of claudin-1, leading to reduction of the expression of claudin-1.\textsuperscript{42} In contrast, claudin-1 reportedly promotes EMT through activation of the c-Abl/ERK signaling pathway\textsuperscript{6} or facilitates invasion by disrupting interaction with the extracellular matrix through MMP.\textsuperscript{8} In this context, high claudin-1 expression is predicted to promote invasion. In the present study, there was no relationship between the expression levels of claudin-1 and metastasis in TSCC patients (Table 2), suggesting that pathological TSCC belonging to “claudin-1-low” type and “claudin-1-high” type coexisted.

**FIGURE 7** Deficiency of claudin-1 promotes motility of SAS cells based on cell motility analysis. A, Claudin-1 expression in mock or claudin-1-knockout SAS cells (generated by gRNA #1 and gRNA #2) was determined by immunoblotting. B-D, Mock or claudin-1-knockout SAS cells (generated by gRNA #1 and gRNA #2) were seeded in 6-well plates (2 × 10\textsuperscript{4} cells/well). After 48 h, cell motility was recorded. Representative random moving traces of 61 cells during a 10-min recording period over 10 h are presented. Scale bar, 50 μm. (E) Summarized data of the migrated distances within 10 h. Data are expressed as means ± SD (n = 10). Student’s t test with two biological independent replicates was used to determine statistical significance; ***P < .001, compared with control.
When we focused on the "claudin-1-high" type, the frequency of cervical lymph node metastasis was significantly higher in the "intracellular claudin-1" group than in the "membrane claudin-1" group (Table 3). The role of claudin-1 as a component of the tight junction may inhibit the invasion. In SAS cells, endocytosis of claudin-1, as well as cell motility, was hindered by the endocytosis inhibitors (Figures 5 and 6). However, the deficiency of claudin-1 in SAS cells increased cell motility (Figure 7). Combining these results, it is possible that the endocytosis-mediated decrease in claudin-1 on the membrane promotes cell motility. Thus, we propose that the endocytosis of claudin-1 at the invasion front could relieve the effect of the persistence of tight junctions to inhibit cell motility in the "claudin-1-high" type.

We also noticed that membrane localization of claudin-1 at the invasion front tended to correlate with higher differentiation (Table 3). Cell polarity is an important aspect of cell differentiation. As claudin-1 is reportedly important in maintaining cell polarity, we speculate that membrane localization of claudin-1 at the invasion front may contribute to maintaining the cell polarity and suppress dedifferentiation.

As tight junction proteins are overexpressed in several types of carcinomas, different approaches using monoclonal antibodies, enterotoxins, and therapeutic gene delivery have been tested as candidates for anticancer drug therapy. The present study suggests that a specific inhibitor of the endocytosis of claudin-1 will be therapeutically valuable to suppress some cases of cancer metastasis, including TSCC.

**ACKNOWLEDGMENTS**

The authors would like to thank Dr Satoshi Yamaguchi, Ms Miwako Hamagaki, Mr Kazuki Takahashi, Dr Yuta Ikami, and Ms Megumi Naito at Tokyo Medical and Dental University (TMDU) for valuable discussions and great support in carrying out the present study. This research was supported by the Project for Promoting Leading-edge Research in Oral Science at Tokyo Medical and Dental University (TMDU) (to KK, KS, HH, SY, TY, TW, HY) and Grants-in-Aid for Scientific Research 17K12005 (to KK, KS, TI, HH, TY, TW, MH).

**CONFLICTS OF INTEREST**

Authors declare no conflicts of interest for this article.

**ORCID**

Miki Hara-Yokoyama https://orcid.org/0000-0002-5621-3625

**REFERENCES**

1. Casiglia J, Woo SB. A comprehensive review of oral cancer. Gen Dent. 2001;49:72-82.
2. Fernandes J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359-E386.
3. Tamura A, Tsukita S. Paracellular barrier and channel functions of TJ claudins in organizing biological systems: advances in the field of barriology revealed in knockout mice. Semin Cell Dev Biol. 2014;36:177-185.
4. Furuse M, Hata M, Furuse K, et al. Claudin-based tight junctions are crucial for the mammalian epidermal barrier: a lesson from claudin-1-deficient mice. J Cell Biol. 2002;156:1099-1111.
5. Bhat AA, Ahmad R, Uppada SB, Singh AB, Dhawan P. Claudin-1 promotes TNF-alpha-induced epithelial-mesenchymal transition and migration in colorectal adenocarcinoma cells. Exp Cell Res. 2016;349:119-127.
6. Suh Y, Yoon C-H, Kim R-K, et al. Claudin-1 induces epithelial-mesenchymal transition through activation of the c-Abl-ERK signaling pathway in human liver cells. Oncogene. 2013;32:4873-4882.
7. Singh AB, Sharma A, Dhawan P. Claudin-1 expression confers resistance to anoikis in colon cancer cells in a Src-dependent manner. Carcinogenesis. 2012;33:2538-2547.
8. Oku N, Sasabe E, Ueta E, Yamamoto T, Otsuki T. Tight junction protein claudin-1 enhances the invasive activity of oral squamous cell carcinoma cells by promoting cleavage of laminin-5 gamma2 chain via matrix metalloproteinase (MMP)-2 and membrane-type MMP-1. Cancer. 2006;66:5251-5257.
9. Chao Y-C, Pan S-H, Yang S-C, et al. Claudin-1 is a metastasis suppressor and correlates with clinical outcome in lung adenocarcinoma. Am J Respir Crit Care Med. 2009;179:123-133.
10. Sheehan GM, Kallakury BV, Sheehan CE, Fisher HA, Kaufman RP Jr, Ross JS. Loss of claudins-1 and -7 and expression of claudins-3 and -4 correlate with prognostic variables in prostatic adenocarcinomas. Hum Pathol. 2007;38:564-569.
11. Yoshida T, Kinugasa T, Akagi Y, et al. Decreased expression of claudin-1 in rectal cancer: a factor for recurrence and poor prognosis. Anticancer Res. 2011;31:2517-2525.
12. Morohoshi S, Kusumi T, Sato F, et al. Decreased expression of claudin-1 correlates with recurrence status in breast cancer. Int J Mol Med. 2007;20:139-143.
13. Ma F, Ding X, Fan Y, et al. A CLDN1-negative phenotype predicts poor prognosis in triple-negative breast cancer. PLoS ONE. 2014;9:e112765.
14. Szasz AM, Tokes AM, Micsinai M, et al. Prognostic significance of claudin expression changes in breast cancer with regional lymph node metastasis. Clin Exp Metas. 2011;28:55-63.
15. Ouban A. Claudin-1 role in colon cancer: an update and a review. Histol Histopathol. 2018;33:1013-1019.
16. Shibutani M, Noda E, Maeda K, Nagahara H, Ohtani H, Hirakawa K. Low expression of claudin-1 and presence of poorly-differentiated tumor clusters correlate with poor prognosis in colorectal cancer. Anticancer Res. 2013;33:3301-3306.
17. Nakagawa S, Miyoshi N, Ishii H, et al. Expression of CLDN1 in colorectal cancer: a novel marker for prognosis. Int J Oncol. 2011;39:791-796.
18. Dhawan P, Singh AB, Deane NG, et al. Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. J Clin Investig. 2005;115:1765-1776.
19. Miwa N, Furuse M, Tsukita S, Niikawa N, Nakamura Y, Furukawa Y. Involvement of claudin-1 in the beta-catenin/Tcf signaling pathway and its frequent upregulation in human colorectal cancers. Oncol Res. 2001;12:469-476.
20. Shen L, Weber CR, Turner JR. The tight junction protein complex undergoes rapid and continuous molecular remodeling at steady state. J Cell Biol. 2008;181:683-695.
21. Dukes JD, Fish L, Richardson JD, et al. Functional ESCRT machinery is required for constitutive recycling of claudin-1 and maintenance of polarity in vertebrate epithelial cells. Mol Biol Cell. 2011;22:3192-3205.
22. Lakoduk AM, Roudot P, Mettlen M, Grossman HM, Schmid SL, Chen PH. Mutant p53 amplifies a dynamin-1/APPL1 endosome feedback loop that regulates recycling and migration. J Cell Biol. 2019;2019:1928-1942.
23. Tsygankova OM, Keen JH. A unique role for clathrin light chain A in cell spreading and migration. J Cell Sci. 2019;132:jcs224030.
24. Koelzer VH, Zlobec I, Lugli A. Tumor budding in colorectal cancer—ready for diagnostic practice? Hum Pathol. 2016;47:4-19.
Yamamoto E, Miyakawa A, Kohama G. Mode of invasion and lymph node metastasis in squamous cell carcinoma of the oral cavity. *Head Neck Surg*. 1984;6:938-947.

Warner GC, Reis PP, Jurisica I, et al. Molecular classification of oral cancer by cDNA microarrays identifies overexpressed genes correlated with nodal metastasis. *Int J Cancer*. 2004;110:857-868.

Yamamoto E, Miyakawa A, Kohama G. Mode of invasion and lymph node metastasis in squamous cell carcinoma of the oral cavity. *Head Neck Surg*. 1984;6:938-947.

Warner GC, Reis PP, Jurisica I, et al. Molecular classification of oral cancer by cDNA microarrays identifies overexpressed genes correlated with nodal metastasis. *Int J Cancer*. 2004;110:857-868.

Dos Reis PP, Bharadwaj RR, Machado J, et al. Claudin 1 overexpression increases invasion and is associated with aggressive histological features in oral squamous cell carcinoma. *Cancer*. 2008;113:3169-3180.

Nishimura N, Sasaki T. Cell-surface biotinylation to study endocytosis and recycling of occludin. *Methods Mol Biol*. 2008;440:89-96.

Cong L, Ran FA, Cox D, et al. Multiplex genome engineering using CRISPR/Cas systems. *Science*. 2013;339:819-823.

Mashiko D, Fujihara Y, Satoh Y, Miyata H, Isotani A, Ikawa M. Claudin-1 overexpression increases invasion and is associated with aggressive histological features in oral squamous cell carcinoma. *Cancer*. 2008;113:3169-3180.

Leech AO, Cruz RG, Hill AD, Hopkins AM. Paradigms lost—an emerging role for over-expression of tight junction adhesion proteins in cancer pathogenesis. *Ann Transl Med*. 2015;3:184.

Supporting Information

Additional supporting information may be found online in the Supporting Information section.